Literature DB >> 21034938

Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group.

Beverly Raney1, Julie Stoner, James Anderson, Richard Andrassy, Carola Arndt, Ken Brown, William Crist, Harold Maurer, Stephen Qualman, Moody Wharam, Eugene Wiener, William Meyer, Andrea Hayes-Jordan.   

Abstract

PURPOSES: The aims of the study were to compare results of clinical/radiographic studies before second-look procedures (SLP) with SLP specimens from patients with gross residual sarcoma at diagnosis and to relate tumor viability to outcome. PATIENTS: Seventy-three patients underwent SLP before completing chemotherapy, with (n = 59) or without (n = 14) radiotherapy. Tumor sites were bladder/prostate (n = 27), head/orbit/parameningeal (n = 22), extremity/trunk (n = 14), and retroperitoneum/pelvis (n = 10).
RESULTS: Of 14 patients, 1 (7%) with clinical/radiographic complete response (CR) had viable tumor. Of 59 patients, 35 (59%) without CR had viable tumor. Five-year failure-free survival (FFS) rates were 81% in 37 patients without viable tumor and 53% in 36 patients with viable tumor (Cox proportional hazards adjusted P = .05). Five-year FFS rates were 67% in 15 patients with clear margins and 43% in 21 patients with tumor-involved margins (n = 18) or viable gross tumor (n = 3) (Cox proportional hazards adjusted P = .04). Five-year survival was 78% to 79% among 73 patients with and 333 patients without SLP during treatment.
CONCLUSIONS: Second-look procedures can show whether viable tumor is present and may be beneficial in selected patients with rhabdomyosarcoma. Disappearance of tumor (CR) usually correlated with no viable tumor at SLP. However, 41% of patients without CR had no viable tumor. Those without viable tumor had increased FFS but not survival compared to those with viable tumor.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21034938      PMCID: PMC3128803          DOI: 10.1016/j.jpedsurg.2010.07.021

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  13 in total

1.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.

Authors:  W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

2.  Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: Results from IRS IV.

Authors:  Carola A S Arndt; Sue Hammond; David Rodeberg; Stephen Qualman
Journal:  J Pediatr Hematol Oncol       Date:  2006-09       Impact factor: 1.289

3.  The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma in children.

Authors:  J Treuner; J Suder; M Keim; P Kaatsch; D Niethammer
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

4.  Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.

Authors:  Giovanni Cecchetto; Elena Carretto; Gianni Bisogno; Patrizia Dall'Igna; Andrea Ferrari; Giovanni Scarzello; Alberto Donfrancesco; Rita Alaggio; Paolo Indolfi; Modesto Carli
Journal:  Pediatr Blood Cancer       Date:  2008-11       Impact factor: 3.167

5.  Value of postchemotherapy bioptical verification of complete clinical remission in previously incompletely resected (stage I and II pT3) malignant mesenchymal tumors in children: International Society of Pediatric Oncology 1984 Malignant Mesenchymal Tumors Study.

Authors:  J Godzinski; F Flamant; A Rey; M T Praquin; H Martelli
Journal:  Med Pediatr Oncol       Date:  1994

6.  The Intergroup Rhabdomyosarcoma Study-II.

Authors:  H M Maurer; E A Gehan; M Beltangady; W Crist; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

7.  The Intergroup Rhabdomyosarcoma Study-I. A final report.

Authors:  H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

8.  Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.

Authors:  David A Rodeberg; Julie A Stoner; Andrea Hayes-Jordan; Simon C Kao; Suzanne L Wolden; Steve J Qualman; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

9.  The Third Intergroup Rhabdomyosarcoma Study.

Authors:  W Crist; E A Gehan; A H Ragab; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann; R Heyn
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  6 in total

Review 1.  What is new in rhabdomyosarcoma management in children?

Authors:  Yasmin Gosiengfiao; Jennifer Reichek; David Walterhouse
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.022

2.  Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:  Timothy B Lautz; Yueh-Yun Chi; Jing Tian; Abha A Gupta; Suzanne L Wolden; Jonathan C Routh; Dana L Casey; Roshni Dasgupta; Douglas S Hawkins; David A Rodeberg
Journal:  Int J Cancer       Date:  2020-02-15       Impact factor: 7.396

3.  Optimal surgical treatment and urological outcomes in boys with pelvic and urogenital rhabdomyosarcomas and soft tissue sarcomas.

Authors:  Tomoro Hishiki; Takeshi Saito; Tetsuya Mitsunaga; Mitsuyuki Nakata; Elena Terui; Shugo Komatsu; Naoko Mise; Kazuaki Harada; Jun Iwai; Yasuyuki Higashimoto; Yuri Okimoto; Harumi Kakuda; Hidemasa Ochiai; Moeko Hino; Sumie Homma; Yuichi Osa; Hideo Yoshida
Journal:  Pediatr Surg Int       Date:  2013-10       Impact factor: 1.827

4.  Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients.

Authors:  Maha A T Elsebaie; Mohamed Amgad; Ahmed Elkashash; Ahmed Saber Elgebaly; Gehad Gamal E L Ashal; Emad Shash; Zeinab Elsayed
Journal:  Sci Rep       Date:  2018-06-19       Impact factor: 4.379

Review 5.  The surgical management of paediatric bladder and prostate rhabdomyosarcoma.

Authors:  Hsi-Yang Wu
Journal:  Arab J Urol       Date:  2012-12-11

Review 6.  Rhabdomyosarcoma in adolescent and young adult patients: current perspectives.

Authors:  Daniela Egas-Bejar; Winston W Huh
Journal:  Adolesc Health Med Ther       Date:  2014-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.